Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition. (Q39192248)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

main subject

chronic myeloid leukemia

0 references

leukemia

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Pavel Simara

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Irena Koutna

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

David Potesil

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Lenka Tesarova

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Michaela Potesilova

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Zbynek Zdrahal

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jiri Mayer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

27 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Hematology

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

385-393

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

24 February 2020

cites work

1 reference

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

Translation of the Philadelphia chromosome into therapy for CML.

21 January 2018

1 reference

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

21 January 2018

1 reference

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

21 January 2018

1 reference

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

21 January 2018

1 reference

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis

21 January 2018

1 reference

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells

21 January 2018

1 reference

Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2.

21 January 2018

1 reference

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

21 January 2018

1 reference

BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.

21 January 2018

1 reference

BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia

21 January 2018

1 reference

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines

21 January 2018

1 reference

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

21 January 2018

1 reference

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells

21 January 2018

1 reference

Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells

21 January 2018

1 reference

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

21 January 2018

1 reference

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.

21 January 2018

1 reference

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

21 January 2018

1 reference

P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib

21 January 2018

1 reference

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

21 January 2018

1 reference

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23419

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23420553%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference